Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
C$0.00
C$0.07
C$0.32
N/AN/A607 shsN/A
(ITC) stock logo
ITC
(ITC)
$45.50
$0.00
$30.33
$47.46
N/AN/A1.80 million shsN/A
UiPath Inc. stock logo
PATH
UiPath
$19.54
+3.4%
$22.55
$12.38
$27.87
$11.12B0.968.83 million shs5.81 million shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$4.69
-2.7%
$6.55
$3.26
$13.51
$303.21M-0.63864,759 shs544,102 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(ITC) stock logo
ITC
(ITC)
0.00%0.00%0.00%0.00%0.00%
UiPath Inc. stock logo
PATH
UiPath
+0.72%-3.08%-17.78%-19.77%+23.11%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
+5.70%-4.74%-26.97%-11.72%-63.62%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/AN/AN/AN/AN/A
(ITC) stock logo
ITC
(ITC)
N/AN/AN/AN/AN/AN/AN/AN/A
UiPath Inc. stock logo
PATH
UiPath
3.9389 of 5 stars
4.34.00.00.02.64.20.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.4947 of 5 stars
3.41.00.04.11.53.30.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/A
(ITC) stock logo
ITC
(ITC)
N/AN/AN/AN/A
UiPath Inc. stock logo
PATH
UiPath
2.50
Moderate Buy$27.4140.29% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.75
Moderate Buy$14.94218.50% Upside

Current Analyst Ratings

Latest GETB, ITC, CKT, TERN, and PATH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2024
UiPath Inc. stock logo
PATH
UiPath
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$27.00
4/1/2024
UiPath Inc. stock logo
PATH
UiPath
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$29.00
3/27/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $18.00
3/20/2024
UiPath Inc. stock logo
PATH
UiPath
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
3/20/2024
UiPath Inc. stock logo
PATH
UiPath
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$29.00
3/20/2024
UiPath Inc. stock logo
PATH
UiPath
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
3/18/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00
3/15/2024
UiPath Inc. stock logo
PATH
UiPath
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$23.00 ➝ $25.00
3/15/2024
UiPath Inc. stock logo
PATH
UiPath
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $30.00
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$5.50
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/AN/AN/A
(ITC) stock logo
ITC
(ITC)
N/AN/AN/AN/AN/AN/A
UiPath Inc. stock logo
PATH
UiPath
$1.31B8.50N/AN/A$3.54 per share5.52
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$1M303.21N/AN/A$4.13 per share1.14

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/A0.00N/AN/AN/AN/AN/AN/A
(ITC) stock logo
ITC
(ITC)
N/AN/A0.00N/AN/AN/AN/AN/A
UiPath Inc. stock logo
PATH
UiPath
-$89.88M-$0.17N/A977.00N/A-6.87%-3.29%-2.36%5/22/2024 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)

Latest GETB, ITC, CKT, TERN, and PATH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.29N/A-$0.29N/AN/A
3/13/2024Q4 2024
UiPath Inc. stock logo
PATH
UiPath
-$0.04$0.06+$0.10$0.06$383.32 million$405.25 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/AN/A
(ITC) stock logo
ITC
(ITC)
$0.861.89%N/AN/AN/A
UiPath Inc. stock logo
PATH
UiPath
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/A
(ITC) stock logo
ITC
(ITC)
N/AN/AN/A
UiPath Inc. stock logo
PATH
UiPath
N/A
3.63
3.63
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
22.39
22.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/A
(ITC) stock logo
ITC
(ITC)
84.21%
UiPath Inc. stock logo
PATH
UiPath
62.50%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/A
(ITC) stock logo
ITC
(ITC)
3.20%
UiPath Inc. stock logo
PATH
UiPath
31.03%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
17.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
147,000N/AN/ANot Optionable
(ITC) stock logo
ITC
(ITC)
N/AN/AN/ANot Optionable
UiPath Inc. stock logo
PATH
UiPath
4,035569.01 million392.45 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
6664.65 million53.40 millionNot Optionable

GETB, ITC, CKT, TERN, and PATH Headlines

SourceHeadline
Terns Pharmaceuticals Inc Ordinary SharesTerns Pharmaceuticals Inc Ordinary Shares
morningstar.com - April 18 at 6:23 PM
Intra-Cellular depression data has investors feeling goodIntra-Cellular depression data has investors feeling good
thepharmaletter.com - April 17 at 3:21 PM
Kumquat Biosciences joins forces with Takeda on I-O developmentKumquat Biosciences joins forces with Takeda on I-O development
thepharmaletter.com - April 17 at 3:21 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
finanznachrichten.de - April 11 at 8:35 AM
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerTerns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
globenewswire.com - April 10 at 4:05 PM
Madrigal announces US launch of NASH/MASH drug RezdiffraMadrigal announces US launch of NASH/MASH drug Rezdiffra
msn.com - April 9 at 10:28 AM
Vivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 millionVivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 million
investing.com - April 5 at 10:17 AM
Vivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockVivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock
insidertrades.com - April 5 at 5:24 AM
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 Shares
insidertrades.com - April 4 at 6:15 AM
This small-cap stock is expected to take off - if its weight-loss pill trial succeedsThis small-cap stock is expected to take off - if its weight-loss pill trial succeeds
morningstar.com - March 30 at 7:03 PM
This small-cap stock is expected to take off — if its weight-loss pill trial succeedsThis small-cap stock is expected to take off — if its weight-loss pill trial succeeds
marketwatch.com - March 28 at 3:24 PM
UBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00UBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00
marketbeat.com - March 27 at 3:09 PM
Here’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime SoonHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
msn.com - March 27 at 9:31 AM
Wall Streets Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
investorplace.com - March 25 at 3:00 PM
Optimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial StabilityOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stability
markets.businessinsider.com - March 21 at 6:49 AM
TERN Apr 2024 15.000 callTERN Apr 2024 15.000 call
finance.yahoo.com - March 16 at 1:45 PM
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
globenewswire.com - March 14 at 4:05 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
finanznachrichten.de - March 12 at 4:18 AM
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaTerns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
globenewswire.com - March 11 at 4:05 PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
globenewswire.com - March 7 at 4:05 PM
Terns Pharmaceuticals to Participate in Upcoming March Investor ConferencesTerns Pharmaceuticals to Participate in Upcoming March Investor Conferences
globenewswire.com - February 27 at 4:05 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
finanznachrichten.de - February 9 at 9:57 AM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive OfficerTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
finanznachrichten.de - February 7 at 5:40 PM
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
finance.yahoo.com - February 7 at 5:40 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cricket Media Group logo

Cricket Media Group

CVE:CKT
Cricket Media Group Ltd. (Cricket Media) is a United States-based education media company. The Company provides content on a learning network for children, families and teachers across the world. Its media brands for toddlers to teens include Babybug, Ladybug, Cricket and Cobblestone. The Company's products include magazines under categories, such as Ask, Cicada, Babybug, Click, Cricket, Cobblestone, Dig, Faces, Ladybug, Muse and Spider; educational toys; books; teacher guides; content library, and Story Bug application. Its Web-based K12 tools for school and home include the ePals community and virtual classroom for global collaboration, as well as In2Books, a Common Core eMentoring program that builds reading, writing and critical thinking skills. It serves teachers, students and parents in over 200 countries and territories through its platform and NeuPals, its joint venture with China-based information technology services company Neusoft.
(ITC) logo

(ITC)

NYSE:ITC
ITC Holdings Corp. (ITC Holdings) is a holding company. The Company is engaged in owning, operating, maintaining and investing in transmission infrastructure. The Company's business consists primarily of the electric transmission operations of its Regulated Operating Subsidiaries. Its Regulated Operating Subsidiaries include International Transmission Company (ITCTransmission), Michigan Electric Transmission Company, LLC (METC), ITC Midwest LLC (ITC Midwest). The operations performed by its Regulated Operating Subsidiaries fall into the various categories, such as asset planning; engineering, design and construction; maintenance, and real time operations. Its customers include investor-owned utilities, municipalities, cooperatives, power marketers and alternative energy suppliers. It owns and operates high-voltage systems in Michigan's Lower Peninsula and portions of Iowa, Minnesota, Illinois, Missouri, Kansas and Oklahoma.
UiPath logo

UiPath

NYSE:PATH
UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform's embedded AI, ML, and NLP capabilities improve decisioning and information processing; emulate human behavior allows organizations to address a myriad of use cases; emulate human behavior allows organizations to address a myriad of use cases; multi-tenant platform enterprise deployment with security and governance and Automation Cloud, which enables customers to begin automating without the need to provision infrastructure, install applications, or perform additional configurations; intuitive interface and low-code, drag-and-drop functionality; signed to enable people and automations to work together; and tracks, measures, and forecasts the performance of automations, enables customers to gain powerful insights and generate key performance indicators with actionable metric. It serves banking and financial services, healthcare, insurance, public sectors, manufacturing, retail, and telecom industries. The company was founded in 2005 and is headquartered in New York, New York.
Terns Pharmaceuticals logo

Terns Pharmaceuticals

NASDAQ:TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.